The Medical Letter on Drugs and Therapeutics
FROM
ISSUE 1561
ISSUE 1561
December 3, 2018
Issue 1561
- Baloxavir Marboxil (Xofluza) for Treatment of Influenza
- Rivaroxaban (Xarelto) plus Aspirin for Secondary Prevention of Cardiovascular Events
- Sodium Zirconium Cyclosilicate (Lokelma) for Hyperkalemia
- Angiotensin II (Giapreza) for Septic Shock
- Clarification: Management of Opioid Withdrawal Symptoms
- IV Aprepitant (Cinvanti) for Chemotherapy-Induced Nausea and Vomiting (online only)
- Juluca - A Two-Drug Complete Regimen for HIV (online only)
Subscribers: Log in to read full issue. Not a subscriber? Subscribe or purchase issue.
Baloxavir Marboxil (Xofluza) for Treatment of Influenza
December 3, 2018 (Issue: 1561)
The FDA has approved baloxavir marboxil (Xofluza –
Shionogi/Genentech), the first polymerase acidic (PA)
endonuclease inhibitor, for single-dose, oral treatment
of acute uncomplicated influenza in patients ≥12 years
old. Baloxavir is the...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.